FMC - dialyzacne sluzby, s.r.o.

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease3 trials
• IgA nephropathy2 trials
• Type 2 diabetes1 trial

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Completed3 trials
• Active, not recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals2 trials
• Bayer1 trial
• Novo Nordisk A/S1 trial

Running trials

• Recruiting

  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  NCT04557462· Phase 3· Novartis Pharmaceuticals· Source

Closed trials

• Completed

  A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

  NCT06522997· Phase 2· Bayer· Source

• Completed

  Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients

  NCT04578834· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease

  NCT03819153· Phase 3· Novo Nordisk A/S· Source